Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 8/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.45 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455247 | 0.89 | CAPN1 (0.52) | GRB2CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL29396765 | 0.89 | CAPN1 (0.52) | GRB2CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL29576210 | 0.86 | CAPN1 (0.55) | GRB2CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL29592022 | 0.85 | ACE (0.47) | GRB2CAPN1CTSBSTAT3 | |
| SCHEMBL30069148 | 0.85 | XIAP (0.52) | GRB2CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL29641846 | 0.84 | GRB2 (0.51) | GRB2CAPN1CTSBSLC6A2XIAP | |
| SCHEMBL31218906 | 0.84 | GRB2 (0.51) | GRB2CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL30185032 | 0.84 | F2 (0.46) | GRB2CAPN1OPRM1OPRD1OPRK1 | |
| SCHEMBL19492652 | 0.83 | CAPN1 (0.62) | GRB2CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL29617972 | 0.82 | ITGB1 (0.45) | GRB2CAPN1OPRM1OPRD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419811-B2 | Hydrogel drug delivery composition | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2025-09-23 | — | — | US | disclosed |
| US-20220218571-A1 | HYDROGEL DRUG DELIVERY COMPOSITION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218571-A1 | HYDROGEL DRUG DELIVERY COMPOSITION | PTH1R, PHPT1, PTMS | GRB2 1124/4885CAPN1 959/4885CTSB 2048/4885 |
| US-12419811-B2 | Hydrogel drug delivery composition | PTH1R, PHPT1, PTMS | GRB2 1124/4885CAPN1 959/4885CTSB 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.